Leukemia, Lymphoma, and Myeloma
10
Page 1 of 1
| Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe) Disease/Condition: Follicular Lymphoma Principal Investigator: Dennis L. Cooper |
| Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Disease/Condition: Smoldering Myeloma Principal Investigator: Madhav V. Dhodapkar |
| Phase III Lenalidomide/Dexamethasone +/- Elotuzumab Previously Untreated Multiple Myeloma Disease/Condition: Multiple Myeloma Principal Investigator: Dhodapkar, Madhav |
| Vorinostat in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma Disease/Condition: Advanced Stage Diffuse Large B-Cell Lymphoma Principal Investigator: Daniel O. Persky |
| A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using PET Imaging Disease/Condition: Hodgkin Lymphoma Principal Investigator: Stuart Evan Seropian |
| A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Disease/Condition: Anaplastic Large Cell Lymphoma (ALCL) | Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral | other transformed T-cell lymphomas Principal Investigator: Francine M Foss |
| An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L Disease/Condition: Post Essential Thromboythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis | Primary Myelofibrosis Principal Investigator: Nikolai Alexandrovich Podoltsev |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma Disease/Condition: Multiple Myeloma Principal Investigator: Madhav Dhodapkar, M.D. |
| Imaging the Effects of Chemotherapy on Cognitive Function in high-grade lymphoma Disease/Condition: Lymphoma Principal Investigator: Herta H Chao |
| Immune Function in T-Cell Lymphoma Disease/Condition: Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral Principal Investigator: Francine M Foss |
| Lenalidomide, Bendamustine and Rituximab Induction Therapy for CLL Disease/Condition: Chronic Lymphocytic Leukemia Principal Investigator: Terri Lynn Parker |
| Ofatumumab vs. Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL (ORCHARDD Trial/ Phase III) Disease/Condition: Diffuse Large B Cell Lymphoma Principal Investigator: Stuart Evan Seropian |
| PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Disease/Condition: Limited-stage Diffuse Large B-Cell Lymphoma Principal Investigator: Daniel O. Persky |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Disease/Condition: Myelodysplastic Syndromes Principal Investigator: Nikolai Alexandrovich Podoltsev |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD Disease/Condition: Graft Versus Host Disease | Leukemia | Myelodysplastic Syndromes Principal Investigator: Warren Shlomchik, MD |
Page 1 of 1
